Investigation of spleen CXCR4 expression by [68Ga]Pentixafor PET in a cohort of 145 solid cancer patients

EJNMMI Research

Hans-Jürgen Wester¹  Peter Herhaus²  Maike Hefter²  Wolfgang Weber³  Valëza Ademaj-Kospiri³  Caroline Anna Peuker⁴  Richard Lewis⁴  Stefan Habringer⁵  Ulrich Keller⁶  Andreas Buck⁷  Rudolf Werner⁷  Malte Kircher⁸  Alexander Gäble⁸  Constantin Lapa⁸ 

[1] Chair of Pharmaceutical Chemistry, Technical University of Munich, Garching, Germany;Clinic and Policlinic for Internal Medicine III, School of Medicine, Technical University of Munich, Munich, Germany;Clinic for Nuclear Medicine, School of Medicine, Technical University of Munich, Munich, Germany;Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Hindenburgdamm 30, 12203, Berlin, Germany;Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Hindenburgdamm 30, 12203, Berlin, Germany;Berlin Institute of Health (BIH), Berlin, Germany;Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Hindenburgdamm 30, 12203, Berlin, Germany;German Cancer Consortium (DKTK), Partner Site Berlin; and German Cancer Research Center (DKFZ), Heidelberg, Germany;Max-Delbrück-Center for Molecular Medicine, Berlin, Germany;Department of Nuclear Medicine, University of Würzburg, Würzburg, Germany;Nuclear Medicine, Medical Faculty, University of Augsburg, Augsburg, Germany;

关键词: Solid tumors;    Clinical studies;    Retrospective studies;    Molecular imaging;    PET;    CXCR4;    Pentixafor;    Spleen;    Uptake;   

DOI  :  10.1186/s13550-021-00822-6

来源: Springer

【 授权许可】

CC BY